左心室辅助装置植入同期瓣膜手术与结局:MOMENTUM 3 试验组合中 HeartMate 3 的多中心综合分析
在 MOMENTUM 3 试验组合的 2200 例 HeartMate 3 左心室辅助装置植入患者中,466 例(21.8%)同期行瓣膜手术。同期瓣膜手术组围术期卒中、出血和右心衰竭发生率更高,但 30 天死亡率和 2 年生存率无差异。作者认为有足够均势考虑开展随机试验评估同期瓣膜手术的获益。
要点
- 同期瓣膜手术组 INTERMACS 1-2 级比例高于单纯左心室辅助装置组(41% vs 31%,P < .05)。
- 同期瓣膜手术组 0 至 30 天卒中(4.9% vs 2.4%)、出血(33.9% vs 23.8%)和右心衰竭(41.5% vs 29.6%)发生率更高(P < .01)。
- 两组 30 天死亡率(3.9% vs 3.3%)和 2 年生存率(81.7% vs 80.8%)无差异。
核心结论
- 左心室辅助装置植入同期瓣膜手术与住院期间并发症增加相关,但对短期和长期生存无影响。
- 作者认为有足够均势考虑开展随机试验评估同期常见瓣膜手术(如二尖瓣或三尖瓣反流矫正)的获益。
研究设计与样本
- 研究纳入 MOMENTUM 3 试验组合中 2200 例植入 HeartMate 3 左心室辅助装置的患者,其中 466 例(21.8%)同期行瓣膜手术。
- 同期瓣膜手术包括 101 例主动脉瓣、61 例二尖瓣、163 例三尖瓣手术,85 例患者行多个瓣膜手术。
- 分析围术期并发症、主要不良事件和生存情况。
主要发现
- 同期瓣膜手术组 INTERMACS 1-2 级比例高于无瓣膜手术组(41% vs 31%,P < .05)。
- 同期瓣膜手术组体外循环时间(124 vs 76 分钟,P < .0001)和住院时间(20 vs 18 天,P < .0001)长于无瓣膜手术组。
- 同期瓣膜手术组 0 至 30 天卒中发生率 4.9% vs 2.4%、出血 33.9% vs 23.8%、右心衰竭 41.5% vs 29.6%(P < .01)。
- 两组 30 天死亡率(3.9% vs 3.3%)和 2 年生存率(81.7% vs 80.8%)无差异。
- 单个瓣膜手术分析与单纯左心室辅助装置植入相比生存无差异;二尖瓣或三尖瓣中重度及以上反流患者无论是否行矫正手术,结局无差异。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Correction of valvular disease is often undertaken during left ventricular assist device (LVAD) implantation with uncertain benefit. We analyzed clinical outcomes with HeartMate 3 (HM3; Abbott) LVAD implantation in those with various concurrent valve procedures (HM3+VP) with those with an isolated LVAD implant (HM3 alone). METHODS: The study included 2200 patients with HM3 implanted within the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3 (MOMENTUM 3) trial portfolio who underwent 820 concurrent procedures among which 466 (21.8%) were HM3+VP. VPs included 101 aortic, 61 mitral, 163 tricuspid; 85 patients had multiple VPs. Perioperative complications, major adverse events, and survival were analyzed. RESULTS: Patients who underwent HM3+VP had higher-acuity Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) profiles (1-2: 41% vs 31%) compared with no VPs (P < .05). The cardiopulmonary bypass time (124 vs 76 minutes; P < .0001) and hospital length of stay (20 vs 18 days; P < .0001) were longer in HM3+VP. A higher incidence of stroke (4.9% vs 2.4%), bleeding (33.9% vs 23.8%), and right heart failure (41.5% vs 29.6%) was noted in HM3+VP at 0 to 30 days (P < .01), with no difference in 30-day mortality (3.9% vs 3.3%) or 2-year survival (81.7% vs 80.8%). Analysis of individual VP showed no differences in survival compared to HM3 alone. No differences were noted among patients with either significant mitral (moderate or worse) or tricuspid (moderate or worse) regurgitation with or without corrective surgery. CONCLUSIONS: Concurrent VPs, commonly performed during LVAD implantation, are associated with increased morbidity during the index hospitalization, with no effect on short- and long-term survival. There is sufficient equipoise to consider a randomized trial on the benefit of commonly performed VPs (such as mitral or tricuspid regurgitation correction), during LVAD implantation.
引用
- John R, Kanwar MK, Cleveland JC, et al. Concurrent valvular procedures during left ventricular assist device implantation and outcomes: A comprehensive analysis of the Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy With HeartMate 3 trial portfolio. J Thorac Cardiovasc Surg. 2022. PMID: 35643769. doi:10.1016/j.jtcvs.2022.04.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。